Truist Financial Issues Positive Forecast for Zymeworks (NASDAQ:ZYME) Stock Price

Zymeworks (NASDAQ:ZYME) had its price objective increased by research analysts at Truist Financial from $35.00 to $36.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial‘s price objective suggests a potential upside of 14.89% from the stock’s current price.

ZYME has been the topic of several other reports. Jefferies Financial Group reissued a “buy” rating and set a $52.00 price objective on shares of Zymeworks in a report on Friday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research report on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Zymeworks in a report on Monday, October 26th. HC Wainwright raised their target price on Zymeworks from $55.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company increased their price objective on shares of Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Zymeworks Trading Up 1.7%

Shares of ZYME stock traded up $0.53 during trading hours on Tuesday, reaching $31.34. 416,053 shares of the stock were exchanged, compared to its average volume of 777,676. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -15.48 and a beta of 1.32. The company’s 50-day moving average price is $27.46 and its 200-day moving average price is $25.38. Zymeworks has a 12-month low of $18.20 and a 12-month high of $31.97.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings results on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.01. The firm had revenue of $512.92 million for the quarter, compared to the consensus estimate of $227.40 million. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%. The company’s revenue for the quarter was up 828.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) earnings per share. On average, sell-side analysts expect that Zymeworks will post 1.32 EPS for the current year.

Insider Activity

In related news, EVP Adam Schayowitz sold 13,832 shares of the business’s stock in a transaction on Friday, October 9th. The stock was sold at an average price of $25.85, for a total transaction of $357,557.20. Following the completion of the transaction, the executive vice president directly owned 23,205 shares of the company’s stock, valued at $599,849.25. The trade was a 37.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 37.73% of the company’s stock.

Institutional Investors Weigh In On Zymeworks

A number of institutional investors and hedge funds have recently bought and sold shares of ZYME. Janney Montgomery Scott LLC increased its stake in shares of Zymeworks by 3.8% in the first quarter. Janney Montgomery Scott LLC now owns 11,487 shares of the company’s stock worth $288,000 after buying an additional 420 shares during the last quarter. Tema ETFs LLC increased its holdings in shares of Zymeworks by 0.7% in the 2nd quarter. Tema ETFs LLC now owns 105,615 shares of the company’s stock worth $2,761,000 after acquiring an additional 684 shares during the period. Tidal Investments LLC grew its holdings in Zymeworks by 0.7% in the 2nd quarter. Tidal Investments LLC now owns 105,615 shares of the company’s stock worth $2,761,000 after buying an additional 684 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Zymeworks by 10.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,507 shares of the company’s stock valued at $221,000 after acquiring an additional 800 shares in the last quarter. Finally, Nykredit A S acquired a new stake in Zymeworks in the second quarter worth about $25,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $56 from $55 and maintained a Buy rating, signaling substantial potential upside in the analyst’s view. Tickerreport article
• Positive Sentiment: Zymeworks raised its 2026 earnings guidance, a favorable update for the company’s near-term outlook. 2026 earnings guidance article
• Neutral Sentiment: Q3 results showed a sharp swing to profit, with EPS of $2.28 versus a loss a year earlier. Revenue was reported above estimates. A $250 million milestone payment from Jazz Pharmaceuticals contributed to the profit, so investors may view some of the results as nonrecurring. Milestone and earnings article
• Negative Sentiment: EPS beat one cited consensus estimate of $2.27 by a penny, but missed the Zacks estimate of $2.40, leaving the earnings comparison mixed. Zacks earnings article

About Zymeworks

Zymeworks Inc is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses.

The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.